These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9220181)

  • 21. Current management of symptomatic atrial fibrillation.
    Haghi D; Schumacher B
    Am J Cardiovasc Drugs; 2001; 1(2):127-39. PubMed ID: 14728042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacologic treatment of atrial fibrillation.
    Bolognesi R
    Cardiovasc Drugs Ther; 1991 Jun; 5(3):617-28. PubMed ID: 1678964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacotherapeutic decision-making for patients with atrial fibrillation.
    Kalus JS
    Am J Health Syst Pharm; 2010 May; 67(9 Suppl 5):S17-25. PubMed ID: 20410532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Newer developments in the management of atrial fibrillation.
    Nattel S
    Am Heart J; 1995 Nov; 130(5):1094-106. PubMed ID: 7484742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atrial fibrillation in the elderly: facts and management.
    Chatap G; Giraud K; Vincent JP
    Drugs Aging; 2002; 19(11):819-46. PubMed ID: 12428993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation.
    Van Gelder IC; Tuinenburg AE; Schoonderwoerd BS; Tieleman RG; Crijns HJ
    Am J Cardiol; 1999 Nov; 84(9A):147R-151R. PubMed ID: 10568674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
    Gillis AM; Verma A; Talajic M; Nattel S; Dorian P;
    Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation. A decision analysis.
    Middlekauff HR; Stevenson WG; Gornbein JA
    Arch Intern Med; 1995 May; 155(9):913-20. PubMed ID: 7726699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefits and risks of catheter ablation in elderly patients with atrial fibrillation.
    Nademanee K; Amnueypol M; Lee F; Drew CM; Suwannasri W; Schwab MC; Veerakul G
    Heart Rhythm; 2015 Jan; 12(1):44-51. PubMed ID: 25257091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Atrial fibrillation in heart failure].
    Costard-Jäckle A
    Herz; 2002 Jun; 27(4):378-87. PubMed ID: 12187868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective use of amiodarone and early cardioversion for postoperative atrial fibrillation.
    Samuels LE; Holmes EC; Samuels FL
    Ann Thorac Surg; 2005 Jan; 79(1):113-6. PubMed ID: 15620926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of the older person with atrial fibrillation.
    Aronow WS
    J Gerontol A Biol Sci Med Sci; 2002 Jun; 57(6):M352-63. PubMed ID: 12023264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etiology, pathophysiology, and treatment of atrial fibrillation: part 1.
    Aronow WS
    Cardiol Rev; 2008; 16(4):181-8. PubMed ID: 18562808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment.
    Blackshear JL; Kopecky SL; Litin SC; Safford RE; Hammill SC
    Mayo Clin Proc; 1996 Feb; 71(2):150-60. PubMed ID: 8577189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacologic management of atrial fibrillation: current therapeutic strategies.
    Lévy S
    Am Heart J; 2001 Feb; 141(2 Suppl):S15-21. PubMed ID: 11174354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation.
    Bray JJH; Warraich M; Whitfield MG; Peter CU; Baral R; Ahmad M; Ahmad S; Abraham GR; Kirresh A; Sahibzada MS; Muzaffar A; Tomson J; Lambiase PD; Captur G; Banerjee A; Providencia R
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD013765. PubMed ID: 36915032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence.
    Slavik RS; Tisdale JE; Borzak S
    Prog Cardiovasc Dis; 2001; 44(2):121-52. PubMed ID: 11568824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antiarrhythmic treatment after reduction of atrial fibrillation by external shock].
    Koenig A; Theolade R; Chauvin M; Brechenmacher C
    Presse Med; 1993 Nov; 22(36):1827-32. PubMed ID: 8309912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study).
    De Simone A; De Pasquale M; De Matteis C; Canciello M; Manzo M; Sabino L; Alfano F; Di Mauro M; Campana A; De Fabrizio G; Vitale DF; Turco P; Stabile G
    Eur Heart J; 2003 Aug; 24(15):1425-9. PubMed ID: 12909071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of the older person with atrial fibrillation.
    Aronow WS
    J Am Geriatr Soc; 1999 Jun; 47(6):740-8. PubMed ID: 10366178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.